GlassScriptPhysician profile
Maria D Hernandez
NPI 1144471608
$196,624.70
in general payments reported to CMS, 2019-2025
30 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,574 · 2020: $14K · 2021: $23K · 2022: $40K · 2023: $7,232 · 2024: $14K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Consulting Fee: $18K · Travel and Lodging: $7,562 · Food and Beverage: $5,923 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,705.13 |
| Consulting Fee | $17,867.50 |
| Travel and Lodging | $7,561.55 |
| Food and Beverage | $5,922.70 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,086.00 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $38,723.57 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $32,407.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $25,358.08 | 2025 | Wegovy |
| Gilead Sciences, INC. | $24,706.15 | 2019-2025 | Livdelzi, Epclusa |
| Ipsen Biopharmaceuticals, INC | $19,937.50 | 2024-2025 | Iqirvo |
| Bausch Health US, LLC | $8,166.58 | 2025 | |
| Sirtex Medical INC | $3,716.15 | 2025 | Sir-Spheres Microspheres |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $939.30 | 2020-2025 | Xifaxan |
| Janssen Biotech, INC. | $415.75 | 2022-2025 | Stelara, Tremfya |
| Lilly USA, LLC | $185.24 | 2024-2025 | Omvoh |
| Mirum Pharmaceuticals, INC. | $144.30 | 2025 | Livmarli |
| Medtronic, INC. | $133.39 | 2021 | |
| Janssen Scientific Affairs, LLC | $130.09 | 2024-2025 | Tremfya |
| Redhill Biopharma INC. | $101.44 | 2021-2024 | Talicia, Aemcolo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $93.48 | 2021-2025 | Entyvio |
| Alkermes, INC. | $92.48 | 2024 | Aristada, Vivitrol, Lybalvi |
| Genzyme Corporation | $55.89 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $40.73 | 2023-2024 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $30.30 | 2023 | |
| Glaxosmithkline, LLC. | $27.02 | 2025 | |
| Celltrion USA INC. | $26.66 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $20.43 | 2024 | |
| Merck Sharp & Dohme LLC | $19.98 | 2024 | Dificid |
| Medline Industries LP | $17.99 | 2025 | |
| Braintree Laboratories, INC. | $17.97 | 2022 | |
| Vivus LLC | $15.93 | 2025 | Pancreaze |
| Celgene Corporation | $14.42 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.